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This paper systematically reviews the published economic research upon cancer genetics services for families at risk of having familial
breast, ovarian or colorectal cancer. A structured search was made of 15 electronic databases. The search identified 1030 papers, of
which 31 fulfilled the inclusion criteria, two were cost–benefit studies, five were cost consequences, four were cost-effectiveness
studies, one was a cost analysis, two were cost-minimisation studies, one was a cost–utility study, 10 modelled life years and six were
reviews. Modelling studies indicate that surveillance, prophylactic and chemoprevention techniques extend survival for carriers of
identified mutations. Genetic testing has been estimated to cost $70–2400 [d48*–1591] and genetic counselling $129–800 [d89–
d551]. The technology of genetic testing has been found to be cost effective. Cost effectiveness was particularly influenced by
targeting genetic services for patients with a strong family history of cancer rather than screening the entire population. Future
economic evaluation must go beyond merely assessing health outcomes and mutation identification, and account for the impact of
genetic services upon the individual, the family and society, establish the value of services to these groups and determine the most
effective ways of delivering genetic services.
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It is estimated that 5–10% of breast cancer cases (King et al, 1993;
Eeles, 1996), 10% of ovarian cancer cases (Easton et al, 1993) and
10–15% of colorectal cancer cases are due to inherited genetic
mutations (Soravia et al, 1997). Women with a BRCA1 mutation
have a lifetime risk of up to 80–90% of developing breast cancer,
40–60% chance of developing ovarian cancer and possibly an
increased risk of developing colorectal cancer (Ford et al, 1994).
Mutations in the hereditary genes nonpolyposis colorectal cancer
(HNPCC) and familial adenomatous polyposis (FAP) predispose
carriers particularly to colorectal cancer. A HNPCC germline
mutation conferes up to an 80–90% lifetime risk of developing
colorectal cancer (Vasen et al, 1996, 1998; Soravia et al, 1997).
Carriers of a FAP mutation have an 80–100% chance of developing
colorectal cancer during their lifetime (Haggitt and Reid, 1986).
Hereditary genes nonpolyposis colorectal cancer and FAP also
convey risks of developing cancers in the duodenum, ureteric tract
and other organs (Vasen et al, 1991; Soravia et al, 1997).
As a consequence of increased awareness among the general
public, there has been demand for genetic assessment services
(Priority Areas Cancer Team, 1998; Ponder, 1999). However, media
speculation suggests that, as a result of the revolution in genetics,
the NHS will become too expensive to run (Sylvester, 2000), posing
the question: what do we currently know about the provision of
cancer genetic services? In this paper, we review the evidence and
issues highlighted in economic evaluations of cancer genetic
services for breast, ovarian and colorectal cancer.
MATERIALS AND METHODS
Search strategy
A structured search was conducted to identify evidence relating to
the economic evaluation of cancer genetic services for families at
risk of having familial breast, ovarian or colorectal cancer. This
was done by means of searching the electronic databases: BMJ
Archive, BIDS, Medline, HealthPromis, DARE, EED, HTA, Cam-
bridge Scientific Abstracts, Econobase, CINAHL, ASSIA, British
Library Catalogue, OCULC WorldCat, Resource Discovery Net-
work and the Cochran Library. Titles, abstracts and articles were
searched for the terms cancer, genetic and economic or cost.
Retrieved papers were hand searched for references that had not
been identified in the electronic search.
Inclusion and exclusion criteria
The criteria for including literature in this paper was as follows:
1. a general review article;
2. a partial or full economic evaluation of treatment;
3. a partial or full economic evaluation of detection or counselling
of individuals for familial cancer.
Research was excluded from the review if it:
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2. examined sporadic cancer;
3. examined a form of genetic cancer other than breast, ovarian or
colorectal cancer such as haemochromatosis;
4. was not an economics paper and only alluded to potential
economic savings;
5. if the term cost had been used to refer to the potentially
negative psychosocial consequences of cancer genetic services.
Data extraction and analysis
All abstracts were obtained and assessed for relevance. All articles
found to be relevant or potentially relevant were obtained and
reviewed in full by one economist to ensure consistency. For all the
empirical papers included in the review, the elements identified in
Drummond et al’s (1997) 10-item checklist for a sound economic
evaluation (see Table 1) were sought. These elements were then
appraised, as were their inter-relationships. Meta-analysis was not
possible due to the diversity in research methods, genetic testing
and interventions used, and reliance on estimated health outcomes
due to a lack of trial, cancer registry and observational data.
For comparative purposes, we have converted all cost estimates
to 2002/3 d and placed them in square brackets. Exchange rates
were taken from the X-rates.com website, while NHS costs
estimates were inflated using the Hospital and Community Pay
and Price Index (Netten and Curtis, 2003). All other costs estimates
were inflated using the HM Treasury GDP Deflator (2003). Authors
who had not identified the year for which their costs were
estimated were contacted and asked to provide this information.
Five authors did not respond. For these five papers, the financial
year was estimated by subtracting 2 years from the date of
publication; these estimates are identified by an * following the
estimate.
RESULTS
Included studies
The search identified 1030 papers, of which 31 fulfilled the
inclusion criteria. Of the 31 papers covering 29 studies, two were
cost–benefit studies, five were cost consequences, four were cost-
effectiveness studies, one was a cost analysis, two were cost-
minimization studies, one was a cost–utility study, 10 modelled
life years (five also considered costs) and six were reviews. The 31
studies are listed in Table 2 and summarised in an Supplementary
Appendix (available at http://www.bangor.ac.uk/healtheconomics/
Text/cancer/litappendix) according to the form of economic
evaluation used in the studies; at times the classification employed
differs from those of the original authors, for example, cost
effectiveness using more than one outcome variable has been
classified as cost-consequences analysis.
Quality assessment
The majority of discrepancies identified in papers related to a lack
of detail provided upon costs and methods. Of the 25 empirical
papers, 15 provided insufficient detail to determine whether or not
they had identified all relevant costs and consequences. A total of
13 papers provided inadequate detail upon the measurement of
costs and consequences. In all, 12 papers were vague or failed to
value costs and consequences credibly. Seven papers did not
discount costs and/or consequences for differential timing. A total
of 14 papers neglected to identify the year for which their costs
were estimated and six papers did not adequately conduct
sensitivity analysis to account for uncertainty in the estimates of
costs and consequences.
DISCUSSION
The body of research conducted over the past decade into cancer
genetic services and technology has been seeking to answer the key
questions: What are the outcomes or the advantages and
disadvantages of cancer genetic testing and services? What are
the financial costs of conducting testing? What value do patients
place upon genetic services? What is the most efficient method of
providing genetic services?
Outcomes of genetic services
Measures To date, health economics research assessing the
advantages and disadvantages of cancer genetics services has
concentrated upon health outcomes such as the number of cancers
detected, the number of mutations detected and, in particular,
modelling survival and quality-adjusted survival (QALYs), ac-
knowledging death and the impact of cancer upon quality of life as
the disadvantages, and diagnosis and survival as the benefits of
genetic services. Exceptions to this were the TRACE project (Brain
et al, 2000; Cohen et al, in press), utilising a range of psychosocial
measures including reasons for attendance at a genetics clinic, and
the work of Wilson et al (1999) assessing the utility of genetic
counselling to past users in terms of process attributes. Similar
findings were reported by Hall et al (1998) in their non-systematic
review of genetic testing, in which they report that evaluations of
genetic diseases have confined themselves to positive health effects
and those utilising a social perspective to the total effects on
individuals. For example, while outcome measures such as the
number of mutations detected, survival in the form of additional
life years gained and QALYS are a suitable outcome for assessing
the cost effectiveness of cancer genetic technology, they ignore the
impact of testing upon families and society, and cost per mutation
ignores the impact upon the individual.
Any future evaluations of cancer genetic services should, where
possible, attempt to account for the impact of genetic services on
the individual, the family and society (Hall et al, 1998). For
individuals, the effects accounted for should include the value of
information, the effects of choice and regret, and any unintended
effects of health interventions. For families and social interaction,
feelings of vulnerability, guilt, blame and continuous watching for
early signs of disease should be considered. At a societal level, the
issues to be addressed include discrimination, equality of access to
technology, social pressure on choice and social expression of
altruism and sympathy (Hall et al, 1998).
While expanding the range of outcomes to be considered is to be
welcomed, this does raise implications for the form of analysis that
can be performed. In the TRACE project (Brain et al, 2000; Cohen
Table 1 Drummond et al’s (1997) 10-item checklist for a sound
economic evaluation
1 Was a well-defined question posed in an answerable form?
2 Was a comprehensive description of the competing alternatives given?
3 Was the effectiveness of the programmes or services established?
4 Were all the important and relevant costs and consequences for each
alternative identified?
5 Were costs and consequences measured accurately in appropriate physical
units?
6 Were costs and consequences valued credibly?
7 Were costs and consequences adjusted for differential timing?
8 Was an incremental analysis of costs and consequences of alternatives
performed?
9 Was allowance made for uncertainty in the establishments of costs and
consequences?
10 Did the presentation and discussion of study results include all issues of
concern to users?
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compare genetic assessment services with typical advice and
surveillance from a breast clinic), cost–benefit, cost–utility and
cost-effectiveness analysis were rejected in favour of a cost-
consequences analysis. Cost–benefit was rejected on the grounds
that the benefits and dis-benefits of the service were largely
unknown and as such could not be valued. Cost–utility was
disregarded due to the difficulty in measuring non-health benefits,
dis-benefits and the psychological health benefits with relatively
insensitive utility measures such as the EuroQol EQ-5D (EuroQol
Group, 1990). Due to the wide range of likely outcomes of the
genetic assessment of women at a high risk of breast cancer, it was
felt that no single outcome could be selected for cost-effectiveness
analysis.
Clearly, there is a need for further research on the psychosocial
impact of genetic services upon the individual, family and society
within a health economics context. There is also a need to assess
the equity of access to genetic services in the light of Steel et al’s
(1999) findings, which indicated that individuals from lower socio-
economic backgrounds are under-represented as patients of
genetics clinics.
Survival and QALYs Although care is required in interpreting the
results of some of the studies modelling life years, given the
variations in parameter estimates used, they have consistently
reported advantages for patients with an identified mutation if
they receive presymptomatic surveillance and/or chemoprevention
or surgical interventions. Vasen et al (1998) and Syngal et al (1999)
have reported additional life years gained for patients at risk of
developing colorectal cancer as a result of a HNPCC mutation.
However, there is considerable divergence in their estimates of life
years gained. Vasen et al (1998) estimated that colonoscopy every
2.5 years compared to no surveillance would provide 6.9 additional
undiscounted life years for a male commencing surveillance at 25
years of age. Syngal et al (1998) found a gain of 13.5 undiscounted
years for an individual opting for surveillance every 3 years from
the age of 25. Despite utilising different mutation penetrance
estimates, convergence was found in the estimated gains in life
years for BRCA1/2-positive women opting for prophylactic surgery
by Schrag et al (1997) and Grann et al (1998). Women opting for
prophylactic mastectomy and oophorectomy at 30 years of age
gained 6–7.6 undiscounted years over women having surveillance
alone (see Table 3). Grann et al (2000, 2002) reported similar
undiscounted findings to those in Table 3 for patients with
moderate penetrance risks, an additional 0.8 years for a woman
having an oophorectomy (Grann et al, 2000), 3.4 years (Grann et al,
2000) and 3.5 years (Grann et al, 2002) for mastectomy, 4.3 years
(Grann et al, 2000) and 4.9 years (Grann et al, 2002) for a woman
having both procedures. Divergence in results (Schrag et al, 1997;
Grann et al, 1998, 2002; Syngal et al, 1998; Vasen et al, 1998;
Wilson et al, 1999) stem from the parameter estimates used, in
particular penetrance estimates, mortality rates and risk reduc-
tions as a result of surveillance and interventions. The modest
gains in life years found in Schrag et al’s (2000) second study is
predominantly a result of the cohort consisting of women at risk of
developing genetic cancer for a second time. In stark contrast to
Schrag et al (1997) and Grann et al (1998, 2000, 2002), Grann et al’s
(1999) study looking at Ashkenazi women found very small gains
in life expectancy for women opting for prophylactic surgery: 38
undiscounted days for a woman having both bilateral mastectomy
Table 2 Form of evaluation
Name Year CB CC CE CA CM CU MLY R D10
Maher et al 1993 P 4/10
Chaliki et al 1995 P (WTP) 1/3
Brown and Kessler 1995, 1996 P 4/10
Heimdal et al 1999 F 7/9
(TRACE) F 9/9
Brain et al 2000
Cohen et al In press
Eccles et al 1998 F 5/9
Lidereau et al 2000 F 5/9
Debniak et al 2000 F 5/9
Sevilla et al 2002 F 8/9
Van Orsouw et al 1999 P 3/9
Cromwell et al 1998 P 7/10
Bapat et al 1999 P 9/10
Wilson et al 1999 F 8/9
Vasen et al 1998 | F 8/10
Syngal et al 1998 P 7/9
Schrag et al 1997 P 6/9
Schrag et al 2000 P 7/9
Grann et al 1998 | F 6/10
Grann et al 1999 | F 7/10
Grann et al 2000 | F 7/10
Grann et al 2002 P 7/9
Tengs et al 1998 P 7/9
Tengs and Berry 2000 | F 8/10
Lerman 1997 | NA
Peters and Biesecker 1997 | NA
Priority Areas Cancer Team 1998 | NA
Hall et al 1998 | NA
Steel et al 1999 | NA
Edwards 2001 | NA
CB¼cost–benefit analysis, CC¼cost-consequences analysis, CE¼cost-effectiveness analysis, CA¼cost analysis, CM¼cost minimisation, CU¼cost–utility analysis,
MLE¼modelling life expectancy, R¼reviews or survey, WTP¼willingness to pay, D10¼proportion of Drummond et al’s (1997) 10-item checklist that were fulfilled. P
indicates a partial economic evaluation and F a full economic evaluation.
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providing genetic testing and surveillance to all Ashkenazi women
and not merely those at increased risk or having a positive
mutation; Ashkenazi Jewish women also have lower mutation
penetrance than women from other ethnic groups (Ford et al,
1995; Struewing et al, 1997).
QALYs gained from surveillance and interventions have been
inconsistent. A woman with a moderate penetrance mutation in
Grann et al (1998) gained 0.2 undiscounted QALYs from having
both mastectomy and oophorectomy compared to 2.1 (Grann et al,
2000) and 2.6 (Grann et al, 2002) undiscounted QALYs in the
revised models. This discrepancy is a result of the change in the
QALY weightings and parameter estimates used in these studies. It
has yet to be proven for genetic cancer that QALY utility scores can
take full account of the psychosocial, physical and economic effects
of testing. Van der Riet et al (1997) in their study modelling costs
and outcomes for couples at risk of having a child with a
monogenic disease state, ‘A traditional cost-effectiveness analysis,
where costs per life years gained or QALY gained are measured, is
not appropriate here since the different dimensions in which
benefits can be expressed cannot be aggregated to a single
summary outcome measure’ (Van der Riet et al, 1997, p 742).
In the case of HNPCC, both genetic testing accompanied by
regular colonoscopy and polypectomy or having prophylactic
surgery (Vasen et al, 1998) have been found to be cost effective in
terms of life years saved. For women with BRCA1/2 mutations,
both chemoprevention and prophylactic interventions have been
found to be cost effective in terms of life years saved (Grann et al,
1998, 2000) and QALYs (Grann et al, 2000; Tengs and Berry, 2000).
However, as is the case for surveillance alone, the benefits from
prophylactic interventions have been found to diminish with older
age or a delay in opting for the intervention (Schrag et al, 1997,
2000; Syngal et al, 1998; Vasen et al, 1998; Grann et al, 2000, 2002),
and the long-term implications of chemoprevention drugs such as
tamoxifen and raloxifene remain to be seen (Grann et al, 2000;
Schrag et al, 2000). The data on QALYs indicates that surveillance
(Syngal et al, 1998; Grann et al, 2000) and chemoprevention
techniques (Grann et al, 2000, 2002) are favoured over prophy-
lactic interventions.
It should be noted that all the modelling studies identified in this
review have confined themselves to looking at identified mutations
(BRCA1, BRCA2 or HNPCC). Families with an unidentified
mutation are known to outnumber those with an identified
mutation (Couch et al, 1997; Stoppa-Lyonnet et al, 1997; Eccles
et al, 1998; Syngal et al, 1999).
Financial cost of genetic services
Laboratory testing There has been some variation in the results
of the studies costing the provision of cancer genetic services.
Estimated costs have ranged between h450 [d334*] and $1000
[d688] (Vasen et al, 1998) [d834*] (Brown and Kessler, 1995, 1996)
for examining the hMLH1 and hMSH2 genes for HNPCC
mutations (Debniak et al, 2000). Only one study considered the
costs of testing for FAP, recoding costs of d207.12 [d234*] for
testing a cancer-affected patient and d90.75 [d102*] for any
subsequent member (Bapat et al, 1999). Familial adenomatous
polyposis testing consisted of a protein truncation test of the APC
gene if searching for the two most common mutations at APC
codons 1061–1063 and 1309–1311 by heteroduplex analysis was
unsuccessful. BRCA estimates have ranged between $70 [d48*] for
a genetic test using extensive multiplex PCR amplification and
two-dimensional electrophoresis (fragments coamplified) of
BRCA1 (Van Orsouw et al, 1999), and $2400 for a full sequence
analysis of the BRCA1 and BRCA2 genes by Myriad Genetics inc
[d1591] (Grann et al, 2000; Lidereau et al, 2000). The disparity in
costs is due to the purchase and maintenance costs of the
respective equipment used, the number of exons searched and
divergence in profit objectives between the public and private
sectors.
Genetic counselling The estimated cost of providing genetic
counselling ranged between $129 [d89] (Cromwell et al, 1998) and
$800 [d551] (Vasen et al, 1998). The most detailed micro-costing of
a single genetics counselling session (breast, ovarian and colorectal
cancer) was conducted at three clinics in Scotland (Wilson et al,
1999), providing a cost estimate of d86 [d94] to d192 [d210] to the
NHS (costs in 1999/2000 d). The cost of counselling is particularly
influenced by staff grade, preparation and counselling time.
The value and utility of genetic services to patients
At present, information upon willingness to pay and the utility to
patients of genetic testing and presymptomatic surveillance for
familial cancer is sparse. The work of Chaliki et al (1995) has
shown that if a token charge were implemented enthusiasm for a
hypothetical offer of testing declined. There is currently no
information upon the monetary value placed upon cancer genetic
services by users and potential service users.
Wilson et al (1999) are the only ones to publish the results of a
discrete choice conjoint analysis exercise with patients of cancer
Table 3 Life years gained for a 30-year-old woman with a BRCA1/2 mutation opting for immediate prophylactic surgery
Additional life years compared to surveillance alone
Scharg et al (1997) Grann et al (1998) Range
Low-risk penetrance BC 40%, OC 5% BC 40%, OC 6%
Oophorectomy 0.3 0.4 0.1
Mastectomy 2.9 2.9 0.0
Oophorectomy and mastectomy 3.2 3.3 0.1
Medium-risk penetrance BC 60%, OC 20% BC 56%, OC 16%
Oophorectomy 1.0 0.9 0.1
Mastectomy 4.1 3.4 0.7
Oophorectomy and mastectomy 5.3 4.5 0.8
High-risk penetrance BC 85%, OC 40% BC 85%, OC 63%
Oophorectomy 1.7 2.6 0.9
Mastectomy 5.3 2.8 2.5
Oophorectomy and mastectomy 7.6 6.0 1.6
BC¼breast cancer penetrance, OC¼ovarian cancer penetrance. All estimates of additional life years are undiscounted.
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offs patients are willing to make between service attributes and
allows competing service configurations to be compared in terms
of utility and cost utility. Although the majority of patients were
found to prefer doctor-led counselling, they were willing to see a
genetics nurse or genetics associate in favour of shorter waiting
times and longer counselling sessions. In terms of patient utility,
genetics nurses and associates were found to be cost effective
compared to doctor-led counselling.
Most efficient method of providing genetic services
Family history vs screening Several studies have looked at the
most effective way of utilising genetic testing. Initially, genetic
testing was assessed as a population-screening tool (Brown and
Kessler, 1995, 1996). Population testing for HNPCC was estimated
to cost up to $2.6 million [d2.17 million*] per mutation detected
(Brown and Kessler, 1995, 1996) and d114240 [d138280] per
BRCA1 mutation detected (Eccles et al, 1998). Having established
the high cost per mutation detected, clinicians and health
economists have sought to target the use of testing to maximise
mutation detection and minimise the expenditure (Tengs and
Berry, 2000; Sevilla et al, 2002). Recent research has highlighted the
efficiency of targeting high-risk cancer-affected patients and family
members of those cancer-affected patients found to be gene
positive (Cromwell et al, 1998; Eccles et al, 1998; Bapat et al, 1999;
Heimdal et al, 1999; Debniak et al, 2000; Lidereau et al, 2000).
There is some variation in the methods used to target cancer-
affected patients and their families from family history alone to
family history in conjunction with laboratory data such as
immunohistochemistry and microsatellite instability. There is
evidence of cost saving and prevention of unnecessary invasive
surveillance techniques when strategic or targeted use is made of
genetic testing, with little or no loss of sensitivity in mutation
detection. Once a mutation is identified in a cancer-affected
relative, any concerned family member can choose to be tested.
Those with the mutation can be targeted for surveillance and those
free of the mutation avoid the need for surveillance.
Widespread testing of entire ethnic groups was proposed by
Grann et al (1999) and Heimdal et al (1999). Heimdal et al (1999)
suspected that the prevalence of BRCA1 in some areas of Norway
might justify considering testing the entire population. Grann et al
(1999) advocated genetic testing for all Ashkenazi Jewish women
for BRCA1/2. This is a result of mutation prevalence being
estimated to be 2.5% in their model. As noted by Grann et al
(1999), cost effectiveness would be improved if targeted testing
based on family history could be conducted; however, frequently
family history information is not available for these families as a
result of small family size and the holocaust.
Cost effectiveness Cost per BRCA1 mutation detected among
members of high-risk families with a living cancer-affected relative
or stored sample of their blood/DNA has been estimated to range
between d74 [d90] (Eccles et al, 1998) and h6881.70 (d4328)
(Sevilla et al, 2002). Estimates of the cost per life years saved by
presymptomatic surveillance and/or prophylactic surgery ranged
between d2100 [d2542] (Priority Areas Cancer Team, 1998) at a 6%
discount rate for members of high-risk families, to $134273
[d101777] (Grann et al, 1999) at a 3% discount rate for
surveillance of all Ashkenazi women. Cost per QALY were
estimated to be $3500–4900 [d2314–3239] for high-risk women,
$15000 [d9916] for women at moderate risk, $34000 [d22477] for
women at slightly increased risk and $1.6 million [d1.06 million]
for women at population risk (Tengs and Berry, 2000). In addition
to targeting high-risk families, cost effectiveness has been found to
be influenced by the outcome measures used, estimated outcomes,
mutation penetrance, mutation prevalence, the accuracy of testing,
the cost of testing, the number of patients counselled per healthy
mutation carrier, the frequency of clinical surveillance, health
interventions employed and their efficacy, uptake and compliance,
the age of the individual when having testing and/or prophylactic
surgery, the proportion of early-to-late-stage cancer detected,
prognosis of any cancer that develops and quality of life (Brown
and Kessler, 1995, 1996; Grann et al, 1998, 1999, 2000; Priority
Areas Cancer Team, 1998; Vasen et al, 1998; Heimdal et al, 1999;
Tengs and Berry, 2000; Sevilla et al, 2002).
Wilson et al (1999) have begun to address the question set by
Lerman (1997) on the most cost-effective way of delivering genetic
services. In the case of counselling, there appears to be
considerable advantage in utilising genetic associates and nurses
rather than doctors and consultants to counsel in appropriate
circumstances. Genetic associates and nurses are less expensive
than consultants and were found to be acceptable to patients,
particularly if this resulted in less travel to genetics counselling
appointments and shorter waiting times. Obviously, there are
many other service options to be considered and assessed.
In conclusion, modelling studies indicate that, for carriers of
identified cancer-predisposing mutations surveillance, prophylac-
tic and chemoprevention techniques extend survival. There is a
need to build upon the findings of these studies and model survival
and QALYs for high-risk patients with unidentified mutations and
patients at moderate risk of developing genetic cancer. Both of
these groups outnumber families with an identified mutation.
Depending upon the service protocols used, genetic testing has
been estimated to cost between $70 and 2400 [d48*–1591] and
genetic counselling between $129 and 800 [d89–551]. The
technology of genetic testing and presymptomatic surveillance
and interventions has been found to be cost effective in terms of
mutations detected, survival and QALYs. Cost effectiveness was
influenced by numerous factors, the main one being targeting
genetic services for patients with a strong family history of cancer
rather than screening the entire population.
In the past economic evaluations of cancer genetics services
have concentrated on health outcomes and mutation identifica-
tion. Future economic evaluation must go beyond health
technology assessment and account for the impact of such services
upon the individual, the family and society, and establish both the
value of services to these groups and the most effective ways of
delivering genetic services, offering counselling and information in
addition to coordinated presymptomatic surveillance and genetic
testing. Any future economic evaluations should also seek to avoid
the deficiencies identified in preceding research relating to lack of
detail upon costs and methods.
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